<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04437927</url>
  </required_header>
  <id_info>
    <org_study_id>20-11</org_study_id>
    <nct_id>NCT04437927</nct_id>
  </id_info>
  <brief_title>Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT</brief_title>
  <official_title>Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Princesse Grace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Princesse Grace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is increasing evidence that [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT is useful&#xD;
      in the identification and treatment of disease processes that involve cardiac inflammation&#xD;
      and infection. Current applications include imaging intra-cardiac device and prosthetic valve&#xD;
      infections, evaluating patients with known or suspected cardiac sarcoidosis or other&#xD;
      inflammatory cardiomyopathies.&#xD;
&#xD;
      However, because normal myocardium can metabolize both glucose and free fatty acids (FFAs),&#xD;
      physiological accumulation of FDG in the myocardium can interfere with the recognition of&#xD;
      abnormal FDG uptake.&#xD;
&#xD;
      The use of a low-carbohydrate diet with a prolonged fast â‰¥ 12 h nutrition followed by a fast&#xD;
      of at least four hours is the effective preparation recommended to suppress physiological&#xD;
      myocardial FDG uptake.&#xD;
&#xD;
      However, the rate of suppression of physiological accumulation of FDG with this method in our&#xD;
      center is only 50%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology :&#xD;
&#xD;
      Group of 30 consecutive patients with cardiac FDG PET prescribed, prospectively enrolled,&#xD;
      compared to a group with the last 30 patients referred for cardiac FDG PET in the nuclear&#xD;
      medicine department of the Centre Hospitalier Princesse Grace.&#xD;
&#xD;
      Procedures :&#xD;
&#xD;
      Infusion of 100mL lipid emulsion for intravenous two hours before cardiac FDG PET/CT:&#xD;
&#xD;
        -  Infusion rate will be 20 mL/hour during the initial 10 minutes (3 mL Intralipid)&#xD;
&#xD;
        -  The dose will be then increased to 40 mL/hour for the next 10 minutes (6 mL Intralipid)&#xD;
&#xD;
        -  Finally, for the next 50 minutes the dose will be increased to 100 mL/hour (83mL&#xD;
           Intralipid)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Actual">November 6, 2020</completion_date>
  <primary_completion_date type="Actual">November 6, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Uptake in the heart scoring according to a visual scale</measure>
    <time_frame>day 1</time_frame>
    <description>Score of 0: complete myocardial suppression&#xD;
Score of 1: incomplete myocardial suppression with increased myocardial FDG uptake hampering myocardial interpretation but not cardiac valves.&#xD;
Score of 2: incomplete myocardial suppression with increased myocardial FDG uptake hampering myocardial and mitral or aortic valve interpretations.&#xD;
Score of 3: incomplete myocardial suppression with increased myocardial FDG uptake hampering myocardial and both mitral and aortic valves interpretations.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Metabolic Preparation</condition>
  <condition>Myocardial Inflammation</condition>
  <arm_group>
    <arm_group_label>Prospective patients</arm_group_label>
    <description>30 consecutive patients with cardiac FDG PET prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>30 patients referred for cardiac FDG PET in the nuclear medicine department of the Centre Hospitalier Princesse Grace</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Group of 30 consecutive patients with cardiac FDG PET prescribed, prospectively enrolled,&#xD;
        compared to a group with the last 30 patients referred for cardiac FDG PET.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with an FDG PET/CT prescribed to explore cardiac disease process&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  renal insufficiency,&#xD;
&#xD;
          -  uncompensated diabetes mellitus,&#xD;
&#xD;
          -  pancreatitis,&#xD;
&#xD;
          -  liver insufficiency,&#xD;
&#xD;
          -  hypothyroidism&#xD;
&#xD;
          -  metabolic disorders&#xD;
&#xD;
          -  sepsis.&#xD;
&#xD;
          -  soy protein allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <country>Monaco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Monaco</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

